+1 (202) 780-3397
Pseudoprogression under checkpoint inhibition therapy
Joint Event on International Conference on Pathology and Infectious Diseases & 3rd International Conference on Pathology and Oncology Research
November 11-12, 2019 | Singapore
Mona Passler
Charite - University Medicine, Germany
Scientific Tracks Abstracts : J Infectious Disease Med Microbiol
Abstract:
A novel agent called checkpoint inhibitor therapy has
revolutionized not only the treatment for several tumor
entities but also our general understanding of oncology.
As more and more patients with solid tumors undergo
this promising immune therapy, new phenomena like
pseudoprogression challenge the clinician.
Pseudoprogression is a temporary increase in tumor size
due to infiltrating leucocytes and edema during checkpoint
inhibitor therapy, which can be mistaken with real progression.
Subsequently, tumor size decreases due to tumor cell
destruction. Pseudoprogression is described in 1.5% - 17% of
all cases - depending on the tumor entity and study. Identifying
pseudoprogression plays a decisive part in successfully using
checkpoint inhibition therapy, because the misinterpretation
of tumor growth might lead to the discontinuation of an
effective treatment, as pseudoprogression indicates a
high likelihood of > 1year survival. In order to guarantee
the best possible treatment, it is crucial to be informed
about pseudoprogression and to know techniques to
distinguish between pseudo- and real progression when
tumor size increases under checkpoint inhibition therapy.
While there are several indicators to differentiate between
the two, ultimately only infiltrating growth– which solely
occurs in malign tumor growth – proves real progression.
Biography:
Mona Passler graduated from Charité Medical University, Berlin, Germany. She is a junior researcher and has worked for several years with Dr. Pietzner and Professor Sehouli from Charité University Berlin specializing with malignant ascites in ovarian cancer and checkpoint inhibition therapy.
E-mail: mona.passler@charite.de
PDF HTML